Market Research Report
Colorectal Cancer - Pipeline Insight, 2022
|Colorectal Cancer - Pipeline Insight, 2022|
DelveInsight Business Research LLP
Content info: 160 Pages
Delivery time: 2-10 business days
DelveInsight's, "Colorectal Cancer - Pipeline Insight, 2022," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Colorectal Cancer Understanding
Colorectal Cancer: Overview
Colorectal cancer refers to cancer in the colon and/or rectum, or both. As the graphic below shows, the colon is part of the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus. Most colorectal cancers develop first as polyps, which are abnormal growths inside the colon or rectum that may later become cancerous if they are not removed. Colorectal cancer (cancer of the colon or rectum) is very treatable when it is discovered early. Even if it spreads into nearby lymph nodes, surgical treatment followed by chemotherapy is very effective. In the most advanced cases - when the cancer has spread to the liver, lungs, or other sites - treatment can often make surgery an option, and can prolong and add to quality of life. Research is constantly being done to learn more and provide hope for people in all colorectal cancer stages.
"Colorectal Cancer - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Colorectal Cancer pipeline landscape is provided which includes the disease overview and Colorectal Cancer treatment guidelines. The assessment part of the report embraces, in depth Colorectal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Colorectal Cancer Emerging Drugs Chapters
This segment of the Colorectal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Colorectal Cancer Emerging Drugs
Patritumab deruxtecan (HER3-DXd, U3-1402) is one of three lead DXd antibody drug conjugates (ADC) in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo's proprietary DXd ADC technology, patritumab deruxtecan is comprised of a human anti-HER3 antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.
Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. Currently, the drug is in Phase III stage of clinical trial evaluation to treat colorectal cancer.
Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in the clinic, is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively. A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS- mutated cancers. As a result, etrumadenant may uniquely block adenosine's immunosuppressive and cancer cell-intrinsic effects.
AL2846 is a c-Met receptor tyrosine kinase (RTK) inhibitor and it also inhibits other RTKs of Flt4, KDR, Axl and Ron being developed by Advenchen Laboratories. Currently, the drug is in Phase I/II stage of clinical trial evaluation to treat colorectal cancer.
Onvansertib is a First-In-Class, Third-Generation, Oral and Highly-Selective PLK1 Inhibitor. The drug is in phase 1/2 of clinical trials for the treatment of patients with colorectal cancer.
Further product details are provided in the report……..
Colorectal Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Colorectal Cancer drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 150+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.
DelveInsight's report covers around 150+ products under different phases of clinical development like
Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Colorectal Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Colorectal Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Colorectal Cancer drugs.
Current Treatment Scenario and Emerging Therapies: